Jarushka Naidoo: Spectrum of ICI toxicity in last 10 years
Jarushka Naidoo shared on X/Twitter:
“Spectrum of ICI toxicity in last 10 years:
– Vigibase pharmacovigilance database
– 25 irAE types, 50,000+patients (84% PD1 mono)
– common irAEs: skin 23% pneumonitis 18.5% colitis 14%
– fatality rate: myocarditis 28% skin 22% pneumonitis 21%
Major gap between trials and reality.”
Visit the article attached to the post.
Source: Jarushka Naidoo/X
Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer, and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.
She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.